Sunovion seeks US FDA's OK for Latuda in bipolar disorder
This article was originally published in Scrip
Sunovion Pharmaceuticals is seeking the US FDA's nod for broader use of the firm’s atypical antipsychotic Latuda (lurasidone HCl) as a monotherapy to treat adults with depressive episodes associated with bipolar I disorder, and as an adjunctive therapy to lithium or valproate for the same indication.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.